• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.005 +0.015 (+1.52%)
Delayed Quote Updated: 3:14 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 407,163
Open 1.000
Bid (Size) 1.000 (1,700)
Ask (Size) 1.010 (2,700)
Prev. Close 0.9900
Today's Range 0.9810 - 1.034
52wk Range 0.9700 - 1.950
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
September 30, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
August 18, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 48.5% below 52-week high
1.005
0.9752W Low 1.9552W High
1 Week 8.6% below 1-week high
0.971W Low 1.101W High

Pliant Therapeutics, Inc. - Common Stock (PLRX) traded between $0.97 and $1.95 over the past 52 weeks and last traded at $1.00, 48.5% below its 52-week high. Over the past week it ranged between $0.97 and $1.10.

Past 12 Months
-4.3%
-11.5%
-11.8%
-26.1%
-19.6%
-32.1%
1W -$0.05
1M -$0.13
3M -$0.14
6M -$0.36
YTD -$0.25
1Y -$0.48

PLRX was -32.1% over the past year, -26.1% over six months, -19.6% year to date, -4.3% in the last week.

12 Months vs Market
PLRX
-32.1%
DIA
+9.7%
SPY
+15.5%
QQQ
+23.4%
IWM
+13.5%

Over the past 12 months PLRX returned -32.1% versus DIA (Dow) +9.7%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +23.4% and IWM (Russell 2000) +13.5%.

Volume & Liquidity 0.83× 3-mo avg
Today 407,163 3-mo avg 492.4K
1W
422.2K
1M
388.0K
3M
492.4K
6M
479.0K
YTD
574.8K
1Y
733.2K

PLRX most recently traded 407,163 shares against a 3-month average daily volume of 492.4K.

More News

Read More
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 11, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
July 13, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 11, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 06, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
April 18, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
March 31, 2026
Via MarketMinute
News headline image
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
March 18, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
March 11, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
February 23, 2026
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
December 04, 2025
Via Chartmill
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
December 04, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
December 01, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 06, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
June 27, 2025
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
June 27, 2025
Via Chartmill
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
June 27, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
May 21, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
May 05, 2025
Via Benzinga
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
May 01, 2025
From Pliant Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Pliant Therapeutics, Inc. - Common Stock publicly traded?
Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?
Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?
The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market
What is the current price of Pliant Therapeutics, Inc. - Common Stock?
The current price of Pliant Therapeutics, Inc. - Common Stock is 1.005
When was Pliant Therapeutics, Inc. - Common Stock last traded?
The last trade of Pliant Therapeutics, Inc. - Common Stock was at 10/08/26 03:14 PM ET
What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 36.12M
How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
Pliant Therapeutics, Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap